Comparative tolerability of newer agents for insomnia

Drug Safety

Volumn 32, Issue 9, 2009, Pages 735-748

  Zammit, Gary ^a,b,c  

^a Clinilabs Inc   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CIMETIDINE; CYTOCHROME P450; DIGOXIN; ERYTHROMYCIN; ESZOPICLONE; FLUCONAZOLE; FLUVOXAMINE; IMIPRAMINE; ITRACONAZOLE; KETOCONAZOLE; LORAZEPAM; OLANZAPINE; PAROXETINE; PLACEBO; PROMETHAZINE; RAMELTEON; RIFAMPICIN; SERTRALINE; THIORIDAZINE; TRIAZOLAM; VENLAFAXINE; WARFARIN; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ABDOMINAL PAIN; ABNORMAL DREAMING; AGITATION; AMNESIA; ANXIETY; ANXIETY DISORDER; AREA UNDER THE CURVE; BEDTIME DOSAGE; BITTER TASTE; CLINICAL TRIAL; CONFUSION; CONTROLLED DRUG RELEASE; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABUSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG LABELING; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSMENORRHEA; EYE PAIN; FALLING; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; LETHARGY; LONG TERM MEMORY; MALAISE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MORNING DOSAGE; NAUSEA; NERVOUSNESS; NEURALGIA; NIGHTMARE; NONHUMAN; NOSE CONGESTION; PARESTHESIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOMOTOR PERFORMANCE; REVIEW; RHINOPHARYNGITIS; SHORT TERM MEMORY; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

AZABICYCLO COMPOUNDS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; HYPNOTICS AND SEDATIVES; INDENES; MEMORY; PIPERAZINES; PSYCHOMOTOR PERFORMANCE; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 68849089462     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11312920-000000000-00000     Document Type: Review

References (141)

1. Lahmeyer H, Wilcox CS, Kann J, et al. Subjective efficacy of zolpidem in outpatients with chronic insomnia: a double-blind comparison with placebo. Clin Drug Invest 1997;13(3): 134-44
2. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994 May; 55 (5): 192-9
3. Maarek L, Cramer P, Attali P, et al. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res 1992 Apr; 20 (2): 162-70
4. Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993 Jan-Feb; 15 (1): 127-36
5. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992 Apr; 20 (2): 150-61
6. Kryger MH, Steljes D, Pouliot Z, et al. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Sleep 1991 Oct; 14 (5): 399-407
7. Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999 Oct; 60 (10): 668-76
8. Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl) 1994 Oct; 116 (2): 130-4
9. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharmacol 1998;13(3): 191-8
10. Dockhorn RJ, Dockhorn DW. Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol 1996 Aug; 19 (4): 333-40
11. Physicians' desk reference. 60th ed. Montvale (NJ): Thomson PDR, 2006
12. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol 1998 Jul; 13 (4): 157-67
13. Roth T, Soubrane C, Titeux L, et al. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006 Aug; 7 (5): 397-406
14. Krystal AD, Erman M, Zammit GK, et al. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008 Jan 1;31(1): 79-90
15. Elie R, Ruther E, Farr I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 1999 Aug; 60 (8): 536-44
16. Walsh JK, Vogel GW, Scharf M, et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000 Feb 1;1(1): 41-9
17. Allain H, Delahaye C, Le Coz F, et al. Postmarketing surveillance of zopiclone in insomnia: analysis of 20,513 cases. Sleep 1991 Oct; 14 (5): 408-13
18. Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004 Dec; 20 (12): 1979-91
19. McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006 Sep; 22 (9): 1633-42
20. Lunesta (eszopiclone) tablets 1 mg, 2 mg and 3 mg: prescribing information [online]. Available from URL: http://www.lunesta.com/ PostedApprovedLabelingText.pdf [Accessed 2009 Jun 17]
21. Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelton in subjects with chronic insomnia. J Clin Sleep Med 2007;3(5): 495-504
22. Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006 Jan; 7 (1): 17-24
23. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006 Jun; 7 (4): 312-8
24. Roth T, Seiden D, Wang-Weigand S, et al. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007 May; 23 (5): 1005-14
25. Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995 Sep; 29 (3): 142-53
26. Darcourt G, Pringuey D, Salliere D, et al. The safety and tolerability of zolpidem: an update. J Psychopharmacol 1999;13(1): 81-93
27. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004;43(4): 227-38
28. Dujardin K, Guieu JD, Leconte-Lambert C, et al. Comparison of the effects of zolpidem and flunitrazepam on sleep structure and daytime cognitive functions: a study of untreated unsomniacs. Pharmacopsychiatry 1998 Jan; 31 (1): 14-8
29. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol 1992;43(6): 597-601
30. Frattola L, Maggioni M, Cesana B, et al. Double blind comparison of zolpidem 20 mg versus flunitrazepam 2 mg in insomniac in-patients. Drugs Exp Clin Res 1990;16(7): 371-6
31. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000 Apr; 59 (4): 865-89
32. Scharf MB, Mayleben DW, Kaffeman M, et al. Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 1991 Feb; 52 (2): 77-83
33. Unden M, Roth-Schechter B. Next day effects after nighttime treatment with zolpidem: a review. Eur Psychiatry 1996;11 Suppl. 1: 21-30S
34. Allain H, Patat A, Lieury A, et al. Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur Psychiatry 1995;10 Suppl. 3: 129-35S
35. Danjou P, Paty I, Fruncillo R, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol 1999 Sep; 48 (3): 367-74
36. Drover D, Lemmens H, Naidu S, et al. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 2000 Dec; 22 (12): 1443-61
37. Mintzer MZ, Griffiths RR. Triazolam and zolpidem: effects on human memory and attentional processes. Psychopharmacology (Berl) 1999 May; 144 (1): 8-19
38. Mintzer MZ, Griffiths RR. Selective effects of zolpidem on human memory functions. J Psychopharmacol 1999;13(1): 18-31
39. Rush CR, Baker RW. Zolpidem and triazolam interact differentially with a delay interval on a digit-enterand-recall task. Hum Psychopharmacol 2001 Mar; 16 (2): 147-57
40. Rush CR, Griffiths RR. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 1996 Apr; 16 (2): 146-57
41. Troy SM, Lucki I, Unruh MA, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 2000 Jun; 20 (3): 328-37
42. Blin O, Micallef J, Audebert C, et al. A double-blind, placebo-and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. J Clin Psychopharmacol 2006 Jun; 26 (3): 284-9
43. Hindmarch I, Legangneux E, Stanley N, et al. A doubleblind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol 2006 Nov; 62 (5): 538-45
44. Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 2006 Dec; 46 (12): 1469-80
45. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998 Nov; 64 (5): 553-61
46. Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003;26(4): 261-82
47. Goa KL, Heel RC. Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986 Jul; 32 (1): 48-65
48. Griffiths AN, Jones DM, Richens A. Zopiclone produces effects on human performance similar to flurazepam, lormetazepam and triazolam. Br J Clin Pharmacol 1986 Jun; 21 (6): 647-53
49. Isawa S, Suzuki M, Uchiumi M, et al. The effect of zolpidem and zopiclone on memory. Nihon Shinkei Seishin Yakurigaku Zasshi 2000 May; 20 (2): 61-9
50. Vermeeren A, Danjou PE, O'Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol 1998;13 Suppl. 2: S98-107
51. Vermeeren A, Riedel WJ, van Boxtel MP, et al. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002 Mar 15;25(2): 224-31
52. Boyle J, Trick L, Johnsen S, et al. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol 2008 Jul; 23 (5): 385-97
53. Eszopiclone (Lunesta), a new hypnotic. Med Lett Drugs Ther 2005 Feb 28;47(1203): 17-9
54. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005;66 Suppl. 9: 31-41
55. Bensimon G, Foret J, Warot D, et al. Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo. Br J Clin Pharmacol 1990 Sep; 30 (3): 463-9
56. Erman MK, Erwin CW, Gengo FM, et al. Comparative efficacy of zolpidem and temazepam in transient insomnia. Hum Psychopharmacol 2001 Mar; 16 (2): 169-76
57. Fleming J, Scharf MB, Moldofsky H, et al. Comparison of residual effects and efficacy of zolpidem, flurazepam and placebo in patients with chronic insomnia. Clin Drug Invest 1995;9(6): 303-13
58. Gieschke R, Cluydts R, Dingemanse J, et al. Effects of bretazenil versus zolpidem and placebo on experimentally induced sleep disturbance in healthy volunteers. Methods Find Exp Clin Pharmacol 1994 Nov; 16 (9): 667-5
59. Morgan PJ, Chapados R, Chung FF, et al. Evaluation of zolpidem, triazolam, and placebo as hypnotic drugs the night before surgery. J Clin Anesth 1997 Mar; 9 (2): 97-102
60. Richens A, Mercer AJ, Jones DM, et al. Effects of zolpidem on saccadic eye movements and psychomotor performance: a double-blind, placebo controlled study in healthy volunteers. Br J Clin Pharmacol 1993 Jul; 36 (1): 61-5
61. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep 1995 May; 18 (4): 246-51
62. Sicard BA, Trocherie S, Moreau J, et al. Evaluation of zolpidem on alertness and psychomotor abilities among aviation ground personnel and pilots. Aviat Space Environ Med 1993 May; 64 (5): 371-5
63. Mintzer MZ, Frey JM, Yingling JE, et al. Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav Pharmacol 1997 Nov; 8 (6-7): 561-74
64. McCall WV. Sleep in the elderly: burden, diagnosis, and treatment. Prim Care Companion J Clin Psychiatry 2004;6(1): 9-20
65. Bocca ML, Le Doze F, Etard O, et al. Residual effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology (Berl) 1999 Apr; 143 (4): 373-9
66. Vermeeren A, O'Hanlon JF, Declerck A, et al. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther 1995;21: 47-64
67. Verster JC, Volkerts ER, Schreuder AH, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol 2002 Dec; 22 (6): 576-83
68. Drake CL, Roehrs TA, Mangano RM, et al. Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia. Hum Psycho-pharmacol 2000 Dec; 15 (8): 595-604
69. Beaumont M, Batejat D, Coste O, et al. Effects of zolpidem and zaleplon on sleep, respiratory patterns and performance at a simulated altitude of 4,000 m. Neuropsychobiology 2004;49(3): 154-62
70. Walsh JK, Pollak CP, Scharf MB, et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000 Jan-Feb; 23 (1): 17-21
71. Hindmarch I, Patat A, Stanley N, et al. Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. Hum Psychopharmacol 2001 Mar; 16 (2): 159-67
72. Rush CR, Frey JM, Griffiths RR. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) 1999 Jul; 145 (1): 39-51
73. Verster JC, Veldhuijzen DS, Patat A, et al. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf 2006 Jan; 1 (1): 63-71
74. Warot D, Bensimon G, Danjou P, et al. Comparative effects of zopiclone, triazolam and placebo on memory and psychomotor performance in healthy volunteers. Fundam Clin Pharmacol 1987;1(2): 145-52
75. Uchiumi M, Isawa S, Suzuki M, et al. The effects of zolpidem and zopiclone on daytime sleepiness and psycho-motor performance. Nihon Shinkei Seishin Yakurigaku Zasshi 2000 Aug; 20 (3): 123-30
76. Tamminen T, Hansen PP. Chronic administration of zopiclone and nitrazepam in the treatment of insomnia. Sleep 1987;10 Suppl. 1: 63-72
77. Ngen CC, Hassan R. A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia. Int Clin Psychopharmacol 1990 Jul; 5 (3): 165-71
78. Ponciano E, Freitas F, Camara J, et al. A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients. Int Clin Psychopharmacol 1990 Apr; 5 Suppl. 2: 69-77
79. Elie R, Lavoie G, Bourgouin J, et al. Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. Int Clin Psychopharmacol 1990 Oct; 5 (4): 279-86
80. Rosenberg R, Caron J, Roth T, et al. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med 2005 Jan; 6 (1): 15-22
81. Gary M, Rubens R, Amato D. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of eszopiclone: a comparison of healthy non-elderly and elderly adults [abstract]. Sleep 2004;27 Suppl.: A56
82. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005 Mar 1;28(3): 303-7
83. Wang-Weigand S, Zammit G, Peng X. Effect of ramelteon on middle-of-the-night balance, mobility, and memory performance in older adults [abstract]. Sleep 2007;30 Suppl.: A244
84. Hajak G, Ebrahim I, Hibberd M, et al. Ramelteon, unlike zopiclone, has no effect on body sway at peak plasma levels in insomnia patients [abstract]. Sleep 2007;30 Suppl.: A245
85. Fry J, Scharf M, Mangano R, et al. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol 2000 May; 15 (3): 141-52
86. Moldofsky H, Lue FA, Mously C, et al. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. J Rheumatol 1996 Mar; 23 (3): 529-33
87. Monti JM, Attali P, Monti D, et al. Zolpidem and rebound insomnia: a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994 Jul; 27 (4): 166-75
88. Perlis ML, McCall WV, Krystal AD, et al. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 2004 Aug; 65 (8): 1128-37
89. Scharf M, Mendels J, Thorpy M, et al. Safety of long-term zolpidem treatment in patients with insomnia. Curr Ther Res 1994;55(9): 1100-11
90. Schlich D, L'Heritier C, Coquelin JP, et al. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 1991 May-Jun; 19 (3): 271-9
91. Allain H, Arbus L, Schuck S, et al. Efficacy and safety of zolpidem administered 'as needed' in primary insomnia: results of a double-blind, placebo-controlled study. Clin Drug Invest 2001;21(6): 391-400
92. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990 Dec; 255 (3): 1246-55
93. Mintzer MZ, Frey JM, Griffiths RR. Zolpidem is differentiated from triazolam in humans using a three-response drug discrimination procedure. Behav Pharmacol 1998 Nov; 9 (7): 545-59
94. Hajak G, Muller WE, Wittchen HU, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003 Oct; 98 (10): 1371-8
95. Soyka M, Bottlender R, Moller HJ. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry 2000 Jul; 33 (4): 138-41
96. Erman M, Krystal A, Zammit G, et al. Long-term efficacy of zolpidem extended-release in the treatment of sleep maintenance and sleep onset insomnia with improvements in next-day functioning [abstract]. Sleep 2007;30 Suppl.: A241
97. Erman M, Krystal A, Zammit G, et al. No evidence of rebound insomnia in patients with chronic insomnia treate with zolpidem extended-release 12.5 mg administered "as needed" 3-7 nights/week for 6 months [abstract]. Sleep 2007;30 Suppl.: A241-2
98. Walsh JK, Fry J, Erwin CW, et al. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Invest 1998;16(5): 347-54
99. Ancoli-Israel S, Walsh JK, Mangano RM, et al. Zaleplon: a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999 Aug; 1 (4): 114-20
100. Ator NA, Weerts EM, Kaminski BJ, et al. Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. Drug Alcohol Depend 2000 Dec 22;61(1): 69-84
101. Ator NA. Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons. Drug Alcohol Depend 2000 Dec 22;61(1): 55-68
102. Jaffe JH, Bloor R, Crome I, et al. A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction 2004 Feb; 99 (2): 165-73
103. Bechelli LP, Navas F, Pierangelo SA. Comparison of the reinforcing properties of zopiclone and triazolam in former alcoholics. Pharmacology 1983;27 Suppl. 2: 235-41
104. Lovett B, Watts D, Grossman M. Prolonged coma after eszopiclone overdose. Am J Emerg Med 2007 Jul; 25 (6): 735 e5-6
105. Krystal A, Walsh JK, Rubens R, et al. Efficacy and safety of six-months of nightly eszopiclone in patients with primary insomnia: a second long term placebo-controlled study [abstract]. Sleep 2006;29 Suppl.: A249
106. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003 Nov 1;26(7): 793-9
107. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005 Nov; 6 (6): 487-95
108. France C, Weltman R, Cruz C, et al. Ramelteon does not have benzodiazepine agonist-like discriminative stimulus effects in normal or diazepam-dependent rhesus monkeys [abstract]. Sleep 2005;28 Suppl.: A45
109. France C, Weltman R, Cruz C. Lack of primary physical dependence effects of ramelteon in rhesus monkeys [abstract]. Sleep 2005;28 Suppl.: A45
110. Nishida N, Sasaki M, Wakasa Y, et al. Reinforcing effect of ramelteon assessed by intravenous self-administration experiments in rhesus monkeys [abstract]. Sleep 2005;28 Suppl.: A45
111. Zammit G, Roth T, Erman M, et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia [abstract]. Sleep 2005;28 Suppl.: A228-9
112. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006 Oct; 63 (10): 1149-57
113. Roehrs T, Rosenthal L, Koshorek G, et al. Effects of zaleplon or triazolam with or without ethanol on human performance. Sleep Med 2001 Jul; 2 (4): 323-32
114. Karim A, Cao C, Zhao Z, et al. Pharmacokinetic interaction between ramelteon (tak-375) and ethanol in healthy adults [abstract]. AAPS J 2004;6(4): R6196
115. Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 2003;17(7): 513-32
116. Wilkinson CJ. The abuse potential of zolpidem administered alone and with alcohol. Pharmacol Biochem Behav 1998 May; 60 (1): 193-202
117. Tuk B, van Gool T, Danhof M. Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. J Pharmacokinet Pharmacodyn 2002 Jun; 29 (3): 235-50
118. Sanchez Garcia P, Paty I, Leister CA, et al. Effect of zaleplon on digoxin pharmacokinetics and pharmacodynamics. Am J Health Syst Pharm 2000 Dec 15;57(24): 2267-70
119. Tolbert D, Karim A, Cao C, et al. Multiple-dose study to assess the effect of ramelteon (tak-375) on the pharmacokinetics of digoxin in healthy subjects [abstract]. AAPS J 2004;6(4): R6195
120. Caron J, Wessel T, Maier G. Evaluation of a pharmaco-kinetic interaction between eszopiclone and diogxin [abstract]. Sleep 2004;27 Suppl.: A55
121. Karim A, Tolbert D, Cao C, et al. Open-label assessment of the pharmacokinetics and pharmacodynamics of warfarin in the presence of multiple doses of ramelteon in healthy adults [abstract]. Sleep 2005;28 Suppl.: A45-6
122. Maier G, Roach J, Rubens R. Evaluation of a pharmaco-kinetic and pharmacodynamic interaction between eszopiclone and warfarin [abstract]. Sleep 2004;27 Suppl.: A56
123. Karim A, Tolbert D, Cao C, et al. Effects of fluconazole and ketoconazole on the pharmacokinetics of ramelteon (TAK-375) in normal healthy male and female subjects [abstract]. Sleep 2004;27 Suppl.: A53-4
124. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 1998 Dec; 64 (6): 661-71
125. Renwick AB, Ball SE, Tredger JM, et al. Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica 2002 Oct; 32 (10): 849-62
126. Karim A, Tolbert D, Cao C, et al. A multiple-dose open-label study to evaluate the effect of rifampin on the pharmacokinetics of ramelteon (tak-375) in healthy men and women [abstract]. AAPS J 2004;6(4): R6197
127. Villikka K, Kivisto KT, Luurila H, et al. Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 1997 Dec; 62 (6): 629-34
128. Desager JP, Hulhoven R, Harvengt C, et al. Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology (Berl) 1988;96(1): 63-6
129. Allard S, Sainati SM, Roth-Schechter BF. Coadministration of short-term zolpidem with sertraline in healthy women. J Clin Pharmacol 1999 Feb; 39 (2): 184-91
130. Hetta J, Broman JE, Darwish M, et al. Psychomotor effects of zaleplon and thioridazine coadministration. Eur J Clin Pharmacol 2000 Jun; 56 (3): 211-7
131. Saul S. Some sleeping pill users range far beyond bed. The New York Times 2006 Mar 8 [online]. Available from URL: http://www.nytimes.com/2006/03/08/ business/08ambien.html [Accessed 2009 Jun 16]
132. Saul S. Study links Ambien use to unconscious food forays. The New York Times 2006 Mar 14 [online]. Available from URL: http://www.nytimes.com/2006/03/ 14/health/14sleep.html [Accessed 2009 Jun 16]
133. Dowd M. Valley of the rolls. The New York Times 2006 Mar 18 [online]. Available from URL: http://select.nytimes.com/2006/03/18/opinion/18dowd.html?-r= 1 [Accessed 2009 Jun 16]
134. Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002 Jul; 3 (4): 323-7
135. Doane JA, Dalpiaz AS. Zolpidem-induced sleep-driving. Am J Med 2008 Nov; 121 (11): e5
136. Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs 2008;22(12): 1021-36
137. Southworth MR, Kortepeter C, Hughes A. Nonbenzodiazepine hypnotic use and cases of "sleep driving". Ann Intern Med 2008 Mar 18;148(6): 486-7
138. Najjar M. Zolpidem and amnestic sleep related eating disorder. J Clin Sleep Med 2007 Oct 15;3(6): 637-8
139. Tsai MJ, Tsai YH, Huang YB. Compulsive activity and anterograde amnesia after zolpidem use. Clin Toxicol (Phila) 2007;45(2): 179-81
140. Chiang A, Krystal A. Report of two cases where sleep related eating behavior occurred with the extended-release formulation but not the immediate-release formulation of a sedative-hypnotic agent. J Clin Sleep Med 2008 Apr 15;4(2): 155-6
141. Najjar M. Zolpidem and amnestic sleep related eating disorder. J Clin Sleep Med 2007 Oct 15;3(6): 637-8